Wall Street Zen Downgrades Edwards Lifesciences (NYSE:EW) to Hold

Key Points

• Wall Street Zen downgraded Edwards Lifesciences to “hold” from “buy,” although the broader analyst consensus remains “Moderate Buy,” with 17 buy ratings and six holds and an average price target of $100.27.
• Edwards reported quarterly EPS of $0.78, beating estimates of $0.74, while revenue reached $1.74 billion and increased 13.6% year over year. The stock opened at $86.39, within its 52-week range of $72.30 to $96.29.
• Insiders sold 5,664 shares worth approximately $511,918 over the past 90 days, while institutional investors—including BlackRock and Bank of New York Mellon—added significant positions; institutions own 79.46% of the company.

Edwards Lifesciences (NYSE:EW - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

EW has been the subject of a number of other reports. Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. BTIG Research reaffirmed a "buy" rating and set a $110.00 price objective on shares of Edwards Lifesciences in a report on Friday, September 11th. Royal Bank Of Canada increased their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. JPMorgan Chase & Co. raised their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Finally, TD Cowen restated a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Stock Performance

EW opened at $86.39 on Friday. The stock has a market capitalization of $49.75 billion, a price-to-earnings ratio of 49.65, a PEG ratio of 2.25 and a beta of 0.85. The company has a fifty day moving average of $88.43 and a 200 day moving average of $85.99. Edwards Lifesciences has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business's quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel Lippis sold 619 shares of the firm's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $87.51, for a total value of $54,168.69. Following the completion of the sale, the vice president directly owned 40,034 shares of the company's stock, valued at $3,503,375.34. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares of the company's stock, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,664 shares of company stock worth $511,918 over the last ninety days. Company insiders own 0.31% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $5,318,092,000. Bank of New York Mellon Corp bought a new position in Edwards Lifesciences during the 2nd quarter valued at about $1,274,082,000. Norges Bank purchased a new stake in Edwards Lifesciences in the 4th quarter worth about $803,686,000. Bank of America Corp DE purchased a new stake in Edwards Lifesciences in the 2nd quarter worth about $605,397,000. Finally, Deutsche Bank AG bought a new stake in Edwards Lifesciences in the second quarter worth about $516,552,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.